A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872

BACKGROUND. Src signaling is markedly upregulated at the invasive glioblastoma (GBM) front following bevacizumab administration. The Src family kinase inhibitor, dasatinib, can effectively block bevacizumab-induced glioma invasion in preclinical models. We hypothesized that combining bevacizumab wit...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer
Egile Nagusiak: Galanis, Evanthia, Anderson, S. Keith, Twohy, Erin L., Carrero, Xiomara W., Dixon, Jesse G., Tran, David Dinh, Jeyapalan, Suriya A., Anderson, Daniel M., Kaufmann, Timothy J., Feathers, Ryan W., Giannini, Caterina, Buckner, Jan C., Anastasiadis, Panos Z., Schiff, David
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788934/
https://ncbi.nlm.nih.gov/pubmed/31290996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32340
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak